1. Home
  2. Labeler Index
  3. Sanofi-aventis U.s. Llc
  4. 0024-5910
  5. Product Images: Kevzara

Product Images Kevzara

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Figure 1 - kevzara 01
  2. Image - kevzara 01a
  3. Image - kevzara 01b
  4. Image - kevzara 01c
  5. Image - kevzara 01d
  6. Image - kevzara 01e
  7. Image - kevzara 01f
  8. Image - kevzara 01g
  9. Image - kevzara 01h
  10. Image - kevzara 01i
  11. Image - kevzara 01j
  12. Image - kevzara 01k
  13. Image - kevzara 01m
  14. Image - kevzara 01n
  15. Image - kevzara 01o
  16. Image - kevzara 01p
  17. Image - kevzara 01q
  18. Image - kevzara 01r
  19. Image - kevzara 01s
  20. Image - kevzara 01t
  21. Image - kevzara 01u
  22. Image - kevzara 01v
  23. Image - kevzara 01w
  24. Image - kevzara 01x
  25. Image - kevzara 01y
  26. Image - kevzara 02
  27. Image - kevzara 03
  28. Image - kevzara 04
  29. Image - kevzara 05
  30. Image - kevzara 06
  31. Image - kevzara 07
  32. Image - kevzara 08
  33. Image - kevzara 09
  34. Image - kevzara 10
  35. Image - kevzara 11
  36. Image - kevzara 12
  37. Image - kevzara 13
  38. Image - kevzara 14
  39. Image - kevzara 15
  40. Image - kevzara 16
  41. Image - kevzara 17
  42. Image - kevzara 18
  43. Image - kevzara 19
  44. Image - kevzara 20
  45. Image - kevzara 21
  46. Image - kevzara 22
  47. Image - kevzara 23
  48. Image - kevzara 24
  49. Image - kevzara 25
  50. PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Syringe Carton - kevzara 26
  51. PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Syringe Carton - kevzara 27
  52. PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Pen Carton - kevzara 28
  53. PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Pen Carton - kevzara 29

Product Label Images

The following 53 images provide visual information about the product associated with Kevzara NDC 0024-5910 by Sanofi-aventis U.s. Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - kevzara 01

Figure 1 - kevzara 01

This is a graph showing the percentage of patients with ACR20 response over the course of a 24-week study. The study involved three groups: a placebo group with methotrexate (MTX), a group taking Kevzara 150 mg with MTX, and a group taking Kevzara 200 mg with MTX. The ACR20 response is measured numerically on the y-axis, and the weeks of the study are plotted on the x-axis.*

Image - kevzara 01a

Image - kevzara 01a

Image - kevzara 01b

Image - kevzara 01b

Image - kevzara 01c

Image - kevzara 01c

Image - kevzara 01d

Image - kevzara 01d

Image - kevzara 01e

Image - kevzara 01e

Image - kevzara 01f

Image - kevzara 01f

Image - kevzara 01g

Image - kevzara 01g

Image - kevzara 01h

Image - kevzara 01h

Image - kevzara 01i

Image - kevzara 01i

Image - kevzara 01j

Image - kevzara 01j

Image - kevzara 01k

Image - kevzara 01k

Image - kevzara 01m

Image - kevzara 01m

Image - kevzara 01n

Image - kevzara 01n

Image - kevzara 01o

Image - kevzara 01o

Image - kevzara 01p

Image - kevzara 01p

Image - kevzara 01q

Image - kevzara 01q

Image - kevzara 01r

Image - kevzara 01r

Image - kevzara 01s

Image - kevzara 01s

Image - kevzara 01t

Image - kevzara 01t

Image - kevzara 01u

Image - kevzara 01u

Image - kevzara 01v

Image - kevzara 01v

Image - kevzara 01w

Image - kevzara 01w

Image - kevzara 01x

Image - kevzara 01x

Image - kevzara 01y

Image - kevzara 01y

Image - kevzara 02

Image - kevzara 02

This text contains information about a medication called "KEVZARA®" (sarilumah), which is an injection with a dosage of 150 mg/114 my. The label also mentions a yellow needle cover and an orange cap. There is no other useful information provided in this text.*

Image - kevzara 03

Image - kevzara 03

This is a description of a prescription drug named KEVZARA®. It is administered via subcutaneous injection using a single-dose prefilled pen that contains 150 mg/1:14 my of the drug. The National Drug Code (NDC) for this medication is 0024.5920.0.*

Image - kevzara 04

Image - kevzara 04

Image - kevzara 05

Image - kevzara 05

Image - kevzara 06

Image - kevzara 06

Image - kevzara 07

Image - kevzara 07

Image - kevzara 08

Image - kevzara 08

Image - kevzara 09

Image - kevzara 09

Image - kevzara 10

Image - kevzara 10

Image - kevzara 11

Image - kevzara 11

Image - kevzara 12

Image - kevzara 12

Image - kevzara 13

Image - kevzara 13

Image - kevzara 14

Image - kevzara 14

Image - kevzara 15

Image - kevzara 15

This is a pre-filled pen containing 200mg of medicine and has a stated dosage of 114. It is meant for single use only and is administered via subcutaneous injection.*

Image - kevzara 16

Image - kevzara 16

Image - kevzara 17

Image - kevzara 17

Image - kevzara 18

Image - kevzara 18

Image - kevzara 19

Image - kevzara 19

Image - kevzara 20

Image - kevzara 20

Image - kevzara 21

Image - kevzara 21

Image - kevzara 22

Image - kevzara 22

Image - kevzara 23

Image - kevzara 23

Image - kevzara 24

Image - kevzara 24

Image - kevzara 25

Image - kevzara 25

PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Syringe Carton - kevzara 26

PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Syringe Carton - kevzara 26

KEVZARA- is a medication that comes as 150 mg/1.14 mL (131.6 mg/mL) injection in 2 single-dose pre-filled syringes designed for subcutaneous use only. The package contains a package insert, medication guide, and instructions for use. Sarilumab is the active ingredient, and each pre-filled syringe holds 114 mL of solution containing 150 mg of it. Other ingredients include arginine, histidine, polysorbate 20, glucose, and sterile water or injection without preservatives. There is no US standard of potency. KEVZARA should be stored in the original carton in a refrigerator at 36°F to 46°F (2°C to 8°C) and should be protected from light. If needed, it can be stored at room temperature up to 77°F (25°C) up to 14 days in the outer carton, but no longer. The enclosed medication guide is required for each patient. More information about dosage and administration can be found in the package insert.*

PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Syringe Carton - kevzara 27

PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Syringe Carton - kevzara 27

This is a description of a medicine packaging containing two single-dose pre-filled syringes, each containing 1.14mL of solution that delivers 200mg of Sarilumab. It includes a medication guide, instructions for use, and dosage information. The solution is sterile and has no preservatives, and it should be stored in a refrigerator at 36°F to 46°F in its original carton to protect it from light. The package insert should be followed, and any unused portion should be discarded in accordance with local requirements. The medicine is for subcutaneous injection use only.*

PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Pen Carton - kevzara 28

PRINCIPAL DISPLAY PANEL - 150 mg/1.14 mL Pen Carton - kevzara 28

KEVZARA (sarilumab) is a medication provided in single-dose pre-filled pens for subcutaneous injection and is used to treat certain autoimmune diseases. Each pen contains 150mg of sarilumab, a solution of arginine, histidine, polysorbate, sucrose and water for injection. Each pen delivers a 50mg dose of the solution. The medication must be refrigerated at 36-46°F and protected from light. The discarded medication must be handled according to guidelines. The package contains dosing information and instructions for use. A medication guide is enclosed for each patient.*

PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Pen Carton - kevzara 29

PRINCIPAL DISPLAY PANEL - 200 mg/1.14 mL Pen Carton - kevzara 29

This is a medication called KEVZARA (sarilumab) which is available in a pre-filled injection pen. It is used for subcutaneous injection and should be stored in a refrigerator at 36°F to 46°F. Dosage information and instructions for use can be found on the package insert. The medication is manufactured by Regeneron, Sanofi Genzyme.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.